Low-dose Ticagrelor in Chinese ACS Patients Undergoing PCI
Status:
Unknown status
Trial end date:
2020-12-14
Target enrollment:
Participant gender:
Summary
Dual Antiplatelet Therapy (DAPT) with aspirin and P2Y12 receptor inhibitor remains a
cornerstone in the secondary prevention of coronary artery disease (CAD). Clopidogrel is one
of the most commonly used antithrombotic agent that inhibits the platelet P2Y(12) adenosine
diphosphate (ADP) receptor.
Ticagrelor is an oral, reversibly-binding, direct-acting P2Y12 receptor antagonist used
clinically for the prevention of atherothrombotic events in patients with acute coronary
syndromes (ACS). Guideline recommendations on the use of dual antiplatelet therapy have been
formulated that ticagrelor 90 mg twice daily plus aspirin in preference to clopidogrel 75mg
daily plus aspirin for ACS patients. The previous studies have reported that half-dose
ticagrelor had the similar inhibitory effect on platelet aggregation as the standard-dose
ticagrelor, which was significantly stronger than that in the clopidogrel group. One-quarter
standard-dose ticagrelor provided greater degree of platelet inhibition than standard dose
clopidogrel in Chinese patients with stable CAD. But the effectiveness and safety of low-dose
ticagrelor remain yet not very clearly in Chinese patients with acute coronary syndrome
undergoing percutaneous coronary intervention.
Phase:
Phase 4
Details
Lead Sponsor:
First Affiliated Hospital of Harbin Medical University